Trial · NCT07877376
Impact of Cognitive Impairment on Chronic Pain in Breast Cancer
NCT07877376, Recruiting, Nadine ATTAL
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of Cognitive Impairment on Chronic Pain in Breast Cancer. Trials, record NCT07877376. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877376
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact of Cognitive Impairment on Chronic Pain in Breast Cancer
- NCT number
- NCT07877376
- Status
- Recruiting
- Enrollment
- 182 participants, estimated
- Lead sponsor
- Nadine ATTAL
- Conditions
- Breast Cancer
- Interventions
- Evaluation of cognitive functions in patients with beast cancer
- First posted
- 2026-10-16
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Prevalence of chronic pain in patients with and without cognitive disorders. | 6 months ± 1 week after completion of chemotherapy | Comparison of the proportion (%) of patients with chronic pain (defined as pain intensity ≥ 4/10 on a numerical pain rating scale, with 0 : no pain and 10 : maximal pain) in patients with cognitive disorders compared to those without cognitive disorders. The presence of cognitive disorders will be based on the global composite score (8 measures assessing various dimensions of cognition). |
| Secondary | Prevalence of chronic pain 2 weeks after completion of chemotherapy in patients with and without cognitive disorders | Two weeks after completion of chemotherapy | Proportion (%) of patients with chronic pain (defined as pain intensity ≥4/10 on a numerical pain rating scale with 0 = no pain and 10 = maximal pain intensity), 2 weeks after completion of chemotherapy in patients with cognitive disorders compared with those without cognitive disorders. |
| Secondary | Affective and sensory dimensions of pain on the short form McGill pain questionnaire | 2 weeks and 6 months after completion of chemotherapy | Affective and sensory dimensions of pain based on the short-form McGill Pain Questionnaire (score out of 12 for the affective dimension and 33 for the sensory dimension) in patients with and without cognitive disorders |
| Secondary | Prevalence of neuropathic pain in patients with or without cognitive disorders | 2 weeks and 6 months after chemotherapy | Proportion (%) of patients with neuropathic pain based on the DN4 questionnaire (10 items). This proportion will be compared in patients with cognitive disorders and those without cognitive disorders |
| Secondary | Characteristics of neuropathic pain | 2 weeks and 6 months after completion of chemotherapy | Characteristic of neuropathic pain based on the Neuropathic Pain Symptom Inventory (NPSI) in patients with and without cognitive disorders. This questionnaire includes 5 dimensions, each scored on a numerical scale from 0 to 10 : Spontaneous burning pain, deep pain, Paroxysmal pain, Evoked pain and Paresthesia/dysesthesia. |
| Secondary | Area of pain | 2 weeks and 6 months after chemotherapy | Area of pain (number of pain sites on a body map) in patients with and without cognitive disorders |
| Secondary | Correlation between pain intensity and cognitive performance | 2 weeks and 6 months after chemotherapy | Correlation between chronic pain intensity (average pain on the Brief Pain Inventory assessed on a 0-10 NRS) and the composite global score (8 cognitive domains) |
| Secondary | Prevalence of chronic pain in those with and without working memory complaints. | 2 weeks and 6 months after chemotherapy | Proportion (%) of patients with chronic pain (defined as pain ≥ 4/10 on the "average pain" item of the Brief Pain Inventory (BPI)), among patients with working memory complaints compared with those without working memory complaints, based on the Working Memory Questionnaire. Scores will be compared with published age- and education-adjusted normative data. |
| Secondary | Prevalence of chronic pain in patients with and without subjective cognitive complaints. | 2 weeks and 6 months after chemotherapy | Proportion (%) of patients with chronic pain ( defined as pain ≥ 4/10 on the "average pain" item of the Brief Pain Inventory (BPI)), in patients with and without subjective cognitive complaints based on the Perceived Cognitive Impairment (PCI) subscale (PCI-18 score \<54 or PCI-20 score \<60). |
| Secondary | Influence of cognitive impairment on pain coping strategies in patients with and without chronic pain | 2 weeks and 6 months after chemotherapy | Influence of cognitive impairment (based on the global composite score) on Pain coping strategies (based on the Coping Strategies Questionnaire (CSQ) scores) in patients with chronic pain and without chronic pain. Chronic pain will be defined as pain ≥ 4/10 on the "average pain" item of the Brief Pain Inventory (BPI). |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07877376
GET https://conductscience.org/api/trials/v1/NCT07877376/registered